Biotricity, Inc.
OTCPK:BTCY Rapporto sulle azioni
Biotricity Dividendi e riacquisti
Dividendo criteri di controllo 0/6 Biotricity non ha registrato alcun pagamento di dividendi.
Informazioni chiave
n/a
Rendimento del dividendo
-3.5%
Rendimento del riacquisto
Rendimento totale per gli azionisti -3.5% Rendimento futuro dei dividendi n/a Crescita dei dividendi n/a Prossima data di pagamento dei dividendi n/a Data di stacco del dividendo n/a Dividendo per azione n/a Rapporto di remunerazione n/a
Aggiornamenti recenti su dividendi e riacquisti
Mostra tutti gli aggiornamenti
Biotricity Kicks Off Another Pilot Program with A Major Hospital System That Services over 800,000 Individuals Sep 20 Biotricity, Inc. announced delayed 10-Q filing Aug 16
Biotricity, Inc. Receives Non-Compliance Letter from Nasdaq Regarding Bid Price Rule Aug 02 Biotricity, Inc., Annual General Meeting, Aug 15, 2024 Jul 25
Biotricity Adds 60-Site, Multi-State Hospital Cardiac Monitoring Pilot Program Jul 11
Biotricity, Inc. Launches Direct-To-Consumer Heart Health Screening Service, Heartsecure, Making Heart Health Services Jun 13 Biotricity, Inc. has filed a Follow-on Equity Offering in the amount of $2.684644 million. May 29
Biotricity Inc. Announces High Demand for Its Latest Device, Biotres Pro Apr 27 Biotricity, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10.55 million. Apr 26
Nasdaq Notifies Biotricity That the Nasdaq Hearings Panel Grants Its Request to Continue Its Listing on Nasdaq Apr 24
Biotricity, Inc. announced that it has received $2 million in funding Apr 10
Biotricity Announces Strategic Partnership for Cardiac Screenings in Patients with Co-Morbidities Apr 04 Biotricity, Inc. announced a financing transaction Mar 27
Biotricity Unveils That Improved Margins Resulted from Latest Advancements to Its Proprietary Cardiac Ai Cloud Platform and Announces Plans for Continued Expansion of Its Cardiac AI Cloud Mar 13 Biotricity, Inc. has filed a Follow-on Equity Offering in the amount of $10.55 million. Feb 29
Biotricity, Inc. has filed a Follow-on Equity Offering in the amount of $10.55 million. Feb 28
Biotricity, Inc. announced delayed 10-Q filing Feb 15
Biotricity, Inc. Receives A Delisting Determination Letter from the Listing Qualifications Department of the Nasdaq Stock Market Feb 03
Investors Give Biotricity, Inc. (NASDAQ:BTCY) Shares A 38% Hiding Jan 26
Biotricity Inc. Expands Development of its Cardiac AI Cloud Platform with Data Ecosystem of over 360 Billion Heartbeats Jan 24
New major risk - Share price stability Jan 18
Second quarter 2024 earnings released: US$0.44 loss per share (vs US$0.57 loss in 2Q 2023) Nov 19
Biotricity, Inc. to Report Q2, 2024 Results on Nov 14, 2023 Nov 11
Biotricity Releases Another Groundbreaking Product: Biotres Pro Nov 01
New major risk - Market cap size Oct 30
Many Still Looking Away From Biotricity, Inc. (NASDAQ:BTCY) Oct 26
Biotricity Continues to Expand Patent Portfolio with Latest Patent Filing for Bioheart Device Oct 11 Biotricity, Inc. Announces Patent Filing for Cutting-Edge Biotres Device Oct 05
Biotricity, Inc. has completed a Follow-on Equity Offering. Sep 21
New major risk - Financial position Aug 17
First quarter 2024 earnings released: US$0.069 loss per share (vs US$0.59 loss in 1Q 2023) Aug 16
Biotricity Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Market Value of Listed Securities Requirement Aug 06
Biotricity Inc. Expands Its Proprietary AI Model and Deepens Relationship with Amazon Aws and Google's Tensor Flow for Remote Cardiac Care Applications Jul 26
Biotricity Regains Nasdaq Listing Compliance Jul 23
Biotricity, Inc. Provides Earnings Guidance for the First Fiscal Quarter Ended June 30, 2023 Jul 07
Full year 2023 earnings released: US$0.38 loss per share (vs US$0.67 loss in FY 2022) Jul 01
Third quarter 2023 earnings: Revenues exceed analyst expectations Feb 16
Biotricity Receives A Letter from Nasdaq Capital Market Regarding Minimum Bid Price Jan 23
Consensus revenue estimates fall by 19% Nov 21
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Nov 16
Price target decreased to US$3.83 Nov 16
Less than half of directors are independent Nov 16
Biotricity, Inc. Launches Cardiac Disease Management Solution Following 2 Successful Pilots with Oklahoma & Kentucky Clinics Oct 27
Less than half of directors are independent Sep 29
Biotricity GAAP EPS of -$0.09, revenue of $2.06M Aug 15
Biotricity Announces Management Changes Aug 13
Biotricity, Inc.: A First Take Jul 28
Biotricity, Inc. announced delayed annual 10-K filing Jun 30
Is Biotricity (NASDAQ:BTCY) Using Debt In A Risky Way? Apr 09
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Feb 15
Biotricity, Inc. to Report Q3, 2022 Results on Feb 14, 2022 Feb 10
High number of new directors Dec 31
Does Biotricity (NASDAQ:BTCY) Have A Healthy Balance Sheet? Dec 11
High number of new directors Nov 17
Biotricity: Capital Raise Leads To Buying Opportunity Aug 31
Biotricity Common Stock Deleted from Other OTC Aug 27
Biotricity, Inc. announced delayed 10-Q filing Aug 18
Biotricity, Inc. Announces Earnings Guidance for the Fiscal 2022 Jun 18
Biotricity, Inc. to Report Q3, 2021 Results on Feb 11, 2021 Feb 09
Biotricity, Inc. announced that it has received $9.5575 million in funding Jan 22
Biotricity Announces New Solution for Personal Heart Management with Bioheart Jan 12
Biotricity, Inc. Prepares 510(k) FDA Filing for Biotres Dec 03
Biotricity Inc. Announces Launch of Its Bioflux® Direct Program Sep 30
Biotricity, Inc. announced a financing transaction Aug 11
Stabilità e crescita dei pagamenti
Recupero dei dati sui dividendi
Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di BTCY siano rimasti stabili in passato.
Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di BTCY siano aumentati.
Rendimento dei dividendi rispetto al mercato Biotricity Rendimento dei dividendi rispetto al mercato
Come si colloca il rendimento da dividendo di BTCY rispetto al mercato? Segmento Rendimento dei dividendi Azienda (BTCY) n/a Fondo del 25% del mercato (US) 1.4% Top 25% del mercato (US) 4.3% Media del settore (Healthcare Services) 1.0% Analista previsionale (BTCY) (fino a 3 anni) n/a
Dividendo notevole: Impossibile valutare il rendimento dei dividendi di BTCY rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.
Dividendo elevato: Impossibile valutare il rendimento dei dividendi di BTCY rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.
Distribuzione degli utili agli azionisti
Copertura degli utili: Dati insufficienti per calcolare il payout ratio di BTCY per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.
Pagamenti in contanti agli azionisti
Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché BTCY non ha segnalato alcun pagamento.
Scoprire le società che pagano dividendi forti Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
